This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Neurocutaneous Diseases  • Alert me on articles by topic

José Gazulla, MD; Isabel Benavente, MD; Manuel Sarasa, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the recent article by Buoni et al¹ in which the authors described a striking improvement in the ataxia in a 3-year-old boy with ataxia-telangiectasia (AT) during treatment with inhaled betamethasone. In spite of the favorable response to the drug, the authors expressed their concern about the adverse effects observed during the trial (weight gain and a cushingoid appearance) and about the safety of betamethasone in an already immunocompromised patient.¹

We recently had the opportunity to treat an adult case of AT, a 34-year-old man born to consanguineous parents.² The neurological exploration revealed gait ataxia with episodic support necessary to walk 10 m, mild distal weakness in the lower extremities, preserved tendon reflexes, and oculomotor apraxia. Administration of a placebo, acetazolamide, and gabapentin rendered no benefit while pregabalin at 225 mg/d improved gait, enabling the patient to walk . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

New Therapies for Ataxia-Telangiectasia—Reply
Sabrina Buoni, Raffaella Zannolli, Livio Sorrentino, and Alberto Fois
Arch Neurol. 2007;64(4):608-609.
EXTRACT | FULL TEXT